1. |
Asa SL, Ezzat S . The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998; 19(6):798-827. doi: 10.1210/edrv.19.6.0350.
|
2. |
Daly AF, Rixhon M, Adam C , et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91(12):4769-75. doi: 10.1210/jc.2006-1668.
|
3. |
Fernandez A, Karavitaki N, Wass JA . Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72(3):377-82. doi: 10.1111/j.1365-2265.2009.03667.x.
|
4. |
Lopes MBS . The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017; 134(4):521-35. doi: 10.1007/s00401-017-1769-8.
|
5. |
Selman WR, Laws ER, Jr., Scheithauer BW , et al. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986; 64(3):402-7. doi: 10.3171/jns.1986.64.3.0402.
|
6. |
Thapar K, Kovacs K, Scheithauer BW , et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38(1):99-106; discussion 106-7. doi: 10.1097/00006123-199601000-00024.
|
7. |
Raverot G, Burman P, McCormack A , et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018; 178(1):G1-g24. doi: 10.1530/eje-17-0796.
|
8. |
Boriachek K, Islam MN, Moller A , et al. Biological functions and current advances in isolation and detection strategies for exosome nanovesicles. Small 2018; 14(6). doi: 10.1002/smll.201702153.
|
9. |
Vlassov AV, Magdaleno S, Setterquist R , et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012; 1820(7):940-8. doi: 10.1016/j.bbagen.2012.03.017.
|
10. |
Del Re M, Biasco E, Crucitta S , et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol 2017; 71(4):680-7. doi: 10.1016/j.eururo.2016.08.012.
|
11. |
Knosp E, Steiner E, Kitz K , et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33(4):610-7; discussion 7-8. doi: 10.1097/00006123-199310000-00008
|
12. |
Corbisier P, Pinheiro L, Mazoua S , et al. DNA copy number concentration measured by digital and droplet digital quantitative PCR using certified reference materials. Anal Bioanal Chem 2015; 407(7):1831-40. doi: 10.1007/s00216-015-8458-z.
|
13. |
Asa SL, Ezzat S . The pathogenesis of pituitary tumors. Annu Rev Pathol 2009; 4(1):97-126. doi: 10.1146/annurev.pathol.4.110807.092259.
|
14. |
Sav A, Rotondo F, Syro LV , et al. Biomarkers of pituitary neoplasms. Anticancer Res 2012; 32(11):4639-54.
|
15. |
Amar AP, Hinton DR, Krieger MD , et al. Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 1999; 2(2):117-22.
|
16. |
Knosp E, Kitz K, Perneczky A . Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989; 25(6):927-30. doi: 10.1227/00006123-198912000-00012
|
17. |
Zhao X, Li J, Huang S , et al. MiRNA-29c regulates cell growth and invasion by targeting CDK6 in bladder cancer. Am J Transl Res 2015; 7(8):1382-9.
|
18. |
Mendrzyk F, Radlwimmer B, Joos S , et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005; 23(34):8853-62. doi: 10.1200/jco.2005.02.8589.
|
19. |
Costello JF, Plass C, Arap W , et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997; 57(7):1250-4.
|
20. |
Bax DA, Mackay A, Little SE , et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 2010; 16(13):3368-77. doi: 10.1158/1078-0432.Ccr-10-0438.
|
21. |
Nagel S, Leich E, Quentmeier H , et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 2008; 22(2):387-92. doi: 10.1038/sj.leu.2405028.
|
22. |
Nebenfuehr S, Bellutti F, Sexl V . Cdk6: at the interface of Rb and p53. Mol Cell Oncol 2018; 5(5):e1511206. doi: 10.1080/23723556.2018.1511206.
|
23. |
Lee KH, Lotterman C, Karikari C , et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009; 9(3):293-301. doi: 10.1159/000186051.
|
24. |
Lim JT, Mansukhani M, Weinstein IB . Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A 2005; 102(14):5156-61. doi: 10.1073/pnas.0501203102.
|
25. |
Wang G, Zheng L, Yu Z , et al. Increased cyclin-dependent kinase 6 expression in bladder cancer. Oncol Lett 2012; 4(1):43-6. doi: 10.3892/ol.2012.695.
doi: 10.3892/ol.2012.695
|
26. |
Symons M, Segall JE . Rac and Rho driving tumor invasion: who’s at the wheel? Genome Biol 2009; 10(3):213. doi: 10.1186/gb-2009-10-3-213.
|
27. |
Liu S, Wang Y, Xue W , et al. Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival. Int J Cancer 2017; 141(4):721-30. doi: 10.1002/ijc.30785.
|
28. |
Vega FM, Ridley AJ . Rho GTPases in cancer cell biology. FEBS Lett 2008; 582(14):2093-101. doi: 10.1016/j.febslet.2008.04.039.
|
29. |
Parri M, Chiarugi P . Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8(1):23. doi: 10.1186/1478-811x-8-23.
|
30. |
Simpson KJ, Dugan AS, Mercurio AM . Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 2004; 64(23):8694-701. doi: 10.1158/0008-5472.Can-04-2247.
|
31. |
Canovas Nunes S, Manzoni M, Pizzi M , et al. The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer J 2018; 8(2):20. doi: 10.1038/s41408-018-0053-z.
|
32. |
Bhavsar PJ, Infante E, Khwaja A , et al. Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration. Oncogene 2013; 32(2):198-208. doi: 10.1038/onc.2012.42.
doi: 10.1038/onc.2012.42
|
33. |
Dart AE, Box GM, Court W , et al. PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion. J Cell Biol 2015; 211(4):863-79. doi: 10.1083/jcb.201501072.
|
34. |
Hodge RG, Ridley AJ . Regulation and functions of RhoU and RhoV. Small GTPases 2017; 30:1-8. doi: 10.1080/21541248.2017.1362495.
|
35. |
Faure S, Fort P . Atypical RhoV and RhoU GTPases control development of the neural crest. Small GTPases 2015; 6(4):174-7. doi: 10.1080/21541248.2015.1025943.
|